Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Watts: Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in.... (0.18 sec) 

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in …

- diabetesjournals.org
GF Watts, PHR Barrett, J Ji, AP Serone, DC Chan, KD … - Diabetes, 2003 - Am Diabetes Assoc
The metabolic syndrome is characterized by insulin resistance and abnormal apolipoprotein
AI (apoAI) and apolipoprotein B-100 (apoB) metabolism that may collectively accelerate
atherosclerosis. The effects of atorvastatin (40 mg/day) and micronised fenofibrate (200 ...
Cited by 110 - Related articles - BL Direct - All 4 versions

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed …

- jlr.org
S Bilz, S Wagner, M Schmitz, A Bedynek, U Keller, … - The Journal of Lipid …, 2004 - ASBMB
Kinetics of apo B and apo AI were assessed in 8 patients with mixed hyperlipidemia at baseline
and after 8 weeks of atorvastatin 80 mg qd and micronised fenofibrate 200 mg qd in a cross-over
study. Both increased hepatic production and decreased catabolism of VLDL accounted ...
Cited by 47 - Related articles - BL Direct - All 5 versions

Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma …


DC Chan, GF Watts, TG Redgrave, TA Mori, PHR … - Metabolism, 2002 - Elsevier
Obesity is strongly associated with dyslipidemia, which may account for the associated increased
risk of atherosclerosis and coronary disease. We aimed to test the hypothesis that kinetics of
hepatic apolipoprotein B-100 (apoB) metabolism are disturbed in men with visceral ...
Cited by 72 - Related articles - BL Direct - All 6 versions

Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma …


GF Watts, DC Chan, PHR Barrett… - International Journal of Obesity, 2003 - nature.com
METHODS: A total of 25 dyslipidaemic obese men were randomized to atorvastatin (n=13) (40
mg/day) or matching placebo (n=12) for 6 weeks. Hepatic secretion and fractional catabolic rate
(FCR) of VLDL-apoB was measured using an intravenous bolus of d 3 -leucine before ...
Cited by 29 - Related articles - BL Direct - All 3 versions

Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in …

- aspetjournals.org
K Ouguerram, T Magot, Y Zair, JS Marchini, B … - Journal of Pharmacology …, 2003 - ASPET
Seven hypertriglyceridemic patients with type-2 diabetes were treated with atorvastatin (40
mg/day) for 2 months. Kinetics of apolipoprotein B100 (apoB100)-containing lipoproteins were
determined before and after atorvastatin treatment and compared with data obtained in ...
Cited by 22 - Related articles - BL Direct - All 5 versions

High-density lipoprotein apolipoprotein AI kinetics in obese insulin resistant …


F Pont, L Duvillard, E Florentin, P Gambert, B … - International journal of …, 2002 - ncbi.nlm.nih.gov
1: Int J Obes Relat Metab Disord. 2002 Sep;26(9):1151-8. High-density lipoprotein
apolipoprotein AI kinetics in obese insulin resistant patients. An in vivo stable isotope
study. Pont F, Duvillard L, Florentin E, Gambert P, Vergès B. ...
Cited by 43 - Related articles - BL Direct - All 4 versions

Recent studies of lipoprotein kinetics in the metabolic syndrome and related …

- nursing2008.com
DC Chan, PHR Barrett, GF Watts - Current opinion in lipidology, 2006 - journals.lww.com
Recent findings: The dysregulation of lipoprotein metabolism may be caused by a combination
of overproduction of VLDL apolipoprotein B-100, decreased catabolism of apolipoprotein B-containing
particles, and increased catabolism of HDL apolipoprotein AI particles. Nutritional ...
Cited by 30 - Related articles - BL Direct - All 7 versions

Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the …


DC Chan, GF Watts, MN Nguyen, PHR … - American Journal of …, 2006 - ajcn.cnfindpark.cn
2 Supported by grants from the National Health and Medical Research Council and the National
Heart Foundation of Australia. Support was also provided by the Raine Medical Research
Foundation, the Royal Perth Hospital Medical Research Foundation, and Pfizer. DCC ...
Cited by 30 - Related articles - BL Direct - All 8 versions

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein …

- diabetesjournals.org
DC Chan, GF Watts, PHR Barrett, LJ Beilin, TG … - Diabetes, 2002 - Am Diabetes Assoc
Hepatic accumulation of lipid substrates perturbs apolipoproteinB-100 (apoB) metabolism in
insulin-resistant, obese subjects and may account for increased risk of cardiovascular
disease. In a placebo-controlled trial, we examined the independent and combined ...
Cited by 92 - Related articles - BL Direct - All 6 versions

Reduction in visceral adipose tissue is associated with improvement in …

- endojournals.org
FM Riches, GF Watts, J Hua, GR Stewart, RP … - Journal of Clinical …, 1999 - Endocrine Soc
We investigated the effect of reduction in visceral obesity on the kinetics of apolipoprotein B-100
(apoB) metabolism in a controlled dietary intervention study in 26 obese men. Hepatic secretion
of very low density lipoprotein (VLDL) apoB was measured using a primed, constant, ...
Cited by 64 - Related articles - BL Direct - All 7 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google